No. 508, Sec. 7
6th Floor Zhongxiao E. Rd. Nangang District
Taipei 115
Taiwan
886 2 2786 6589
https://www.obipharma.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein:
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Ming-Tien Lai | Chief Scientific Officer | 7,73M | S.O. | S.O. |
Mr. Cheng-En Tsai | VP of Medical Department & Director | 7,38M | S.O. | S.O. |
Dr. Heidi Wang Ph.D. | Chief Executive Officer | S.O. | S.O. | S.O. |
Mr. Colin Kao | CFO, Accounting Supervisor & Corporate Governance Supervisor | S.O. | S.O. | S.O. |
Mr. Po-Jen Chang | Director of Human Resources & Administration | S.O. | S.O. | S.O. |
Ms. Sharon Lee | Director of Public Affairs | S.O. | S.O. | S.O. |
Mr. Kevin P. Poulos | Chief Business Officer | S.O. | S.O. | 1959 |
Dr. Wayne Saville M.D. | Chief Medical Officer | S.O. | S.O. | S.O. |
Dr. Dong Xu Ph.D. | Senior Vice President of Biostatistics & Data Management | S.O. | S.O. | S.O. |
Mr. Chun-Hung Chou | Vice President of Chemical Pharmacy and R&D Office | S.O. | S.O. | S.O. |
OBI Pharma, Inc., a biopharma company, develops and licenses novel therapeutic agents for unmet medical needs against cancer in Taiwan and internationally. It offers Adagloxad Simolenin (OBI-822), a breast cancer active immunity anti-cancer drug for generating antibody against tumor surface antigen Globo H; OBI-833, an immunity anti-cancer drug for the treatment of lung cancer; OBI-866 SSEA-4, an active immune-oncology drug; OBI-888, a Globo H monoclonal antibody; OBI-999, an antibody drug conjugate; OBI-3424, a micromolecule chemotherapy prodrug; and OBI-858, a botulinum toxin, as well as OBI-898, OBI-998, and COVID-19 BCVax drugs. The company was founded in 2002 and is headquartered in Taipei, Taiwan.
L’ISS Governance QualityScore de OBI Pharma, Inc. en date du S.O. est S.O.. Les scores principaux sont Audit : S.O.; Société : S.O.; Droits des actionnaires : S.O.; Compensation : S.O..